1477 — Ocumension Therapeutics Income Statement
0.000.00%
- HK$4.89bn
- HK$3.91bn
- CNY246.37m
- 31
- 11
- 61
- 22
Annual income statement for Ocumension Therapeutics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.19 | 13.1 | 56.1 | 159 | 246 |
Cost of Revenue | |||||
Gross Profit | 0.18 | 11.4 | 36.9 | 103 | 144 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,326 | 2,278 | 302 | 559 | 625 |
Operating Profit | -1,325 | -2,265 | -246 | -400 | -378 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -1,325 | -2,265 | -260 | -402 | -379 |
Provision for Income Taxes | |||||
Net Income After Taxes | -1,325 | -2,265 | -260 | -403 | -380 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -1,312 | -2,265 | -260 | -403 | -380 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -1,312 | -2,265 | -260 | -403 | -380 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -2.8 | -7.35 | -0.594 | -0.633 | -0.588 |